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Abstract Of the five cloned somatostatin (SRIF: soma-
totropin release inhibitory factor) receptors (sst1–5), only
sst2 and sst5 receptors appear to be endogenously ex-
pressed and functionally active in AtT-20 mouse anterior
pituitary tumour cells. In this study, the presence and the
functional coupling of SRIF receptors to G-protein in
AtT-20 cells was evaluated by receptor autoradiography
and guanosine-5’-Ο-(3-[35S]thio)-triphosphate ([35S]GTPγS)
binding, respectively. In addition, transcriptional effects
via the serum response element (SRE) were assessed in
AtT-20-SRE-luci cells, engineered to express constitu-
tively SRE upstream of the luciferase reporter gene.
[125I]LTT-SRIF-28, [125I]CGP 23996 and [125I]Tyr3-oc-
treotide binding illustrates the high level of sst2/5 receptor
in AtT-20 cell membranes. SRIF-14 and SRIF-28 pro-
duced a concentration-dependent increase in [35S]GTPγS
binding (pEC50 = 6.72 and 7.45; Emax = 79 and 74.9, re-
spectively) which was completely abolished by pertussis
toxin. sst2/5 receptor-selective ligands caused a concentra-
tion-dependent increase in [35S]GTPγS binding (pEC50 =
7.74–5.84; Emax = 76.6–20.2) while sst1/3/4 receptor-selec-
tive ligands were devoid of activity. The binding profiles
of [125I]LTT-SRIF-28 and the inhibition of cAMP accu-
mulation correlated highly significantly with their corre-
sponding [35S]GTPγS binding profiles (r=0.862 and
0.874, respectively). The effects of the sst2 receptor-pre-
ferring agonists Tyr3-octreotide and BIM 23027 on
[35S]GTPγS binding, but not those of SRIF-14 and the
sst5/1 receptor selective-agonist L-817,818, were competi-
tively antagonised by the sst2 receptor antagonist D-Tyr8-
CYN 154806 (pKB = 7.36 and 7.72, respectively; slope
factors not significantly different from unity). In AtT-20-
SRE-luci cells, which carry a SRE-luciferase construct
functioning in a very efficient manner, SRIF and its ana-
logues did not affect luciferase activity.
Taken together, these results demonstrate that in AtT-20
cells the expression of sst2 and sst5 receptors fit with their
functional coupling to Gi/o-proteins. The pharmacological
implications of the existence of different ligand/receptor
complexes are discussed. However, the intracellular path-
ways coupled to the activation of sst2 and sst5 receptors
appear not to modulate the SRE-mediated transcriptional
activity, suggesting that SRIF effects on gene expression
coupled to mechanisms that have promoters other than
SRE.
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Introduction
The cyclic neuropeptide somatostatin (SRIF: somato-
tropin release inhibitory factor) exhibits multiple biologi-
cal effects, which include the inhibition of several pitu-
itary hormones (Patel 1999). The effects of SRIF are me-
diated via its interaction with specific membrane bound
receptors, five subtypes of which have been characterized
by molecular cloning from mammalian species, and
termed sst1–5; these receptors belong to the seven trans-
membrane spanning superfamily of G-protein-coupled re-
ceptors (Hannon et al. 2002). To date, although numerous
studies have explored SRIF receptor function when ex-
pressed in recombinant systems, specific physiological re-
sponses of native receptor subtypes are generally un-
known. This is particularly true in cells that express sev-
eral subtypes of SRIF receptors, which tend to show par-
tially overlapping pharmacological and transductional
features that confuse the interpretation of mechanistic
studies. Another reason is the lack of subtype specific ag-
onists/antagonists with adequate pharmacokinetic proper-
Davide Cervia · Dominique Fehlmann · Daniel Hoyer
Native somatostatin sst2 and sst5 receptors 
functionally coupled to Gi/o-protein, but not to the serum response element 
in AtT-20 mouse tumour corticotrophs
Naunyn-Schmiedeberg’s Arch Pharmacol (2003) 367 : 578–587
DOI 10.1007/s00210-003-0752-1
Received: 12 February 2003 / Accepted: 17 March 2003 / Published online: 15 May 2003
ORIGINAL ARTICLE
D. Cervia (✉)
Dipartimento di Fisiologia e Biochimica “G. Moruzzi”, 
Università di Pisa, 56127 Pisa, Italy
Tel.: +39-050-2213459, Fax: +39-50-2213527,
e-mail: d.cervia@dfb.unipi.it
D. Fehlmann · D. Hoyer
Nervous System Research, WSJ-386/745, Novartis Pharma AG,
4002 Basel, Switzerland
© Springer-Verlag 2003
